- Home
- AMRN vs FLC Comparison
AMRN vs FLC Comparison
Compare AMRN & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.59
Company Overview
Basic Information| Metric | AMRN | FLC |
|---|---|---|
| Founded | 1989 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 184.0M |
| IPO Year | 1998 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AMRN | FLC |
|---|---|---|
| Price | $14.59 | $16.60 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 78.6K | 18.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $0.39 | $14.80 |
| 52 Week High | $20.90 | $18.09 |
Technical Indicators
Market Signals| Indicator | AMRN | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 31.59 |
| Support Level | $14.65 | $16.35 |
| Resistance Level | $16.95 | $17.68 |
| Average True Range (ATR) | 0.74 | 0.22 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 31.16 | 12.56 |
Price Performance
Historical Comparison AMRN
FLC
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.